Konferenzen  >  Medizin & Gesundheitswesen  >  Onkologie  >  Virtuelle Veranstaltung

The European Association for Cancer Research (EACR)

This conference will explore a breadth of new technical approaches to the identification and development of novel cancer therapeutics, including agents in early clinical development. The aim is to provide an accessible insight into recent developments in this rapidly evolving field, that aims to harness our insights from cancer research for the benefit of patients. The target audience for this conference is: scientists in academia and industry who are interested in the most recent developments in cancer therapeutic discovery, including small molecule, degrader, peptide, and antibody technologies. The conference will include several novel antitumour approaches in early clinical development. Join us online on 24 and 25 September to learn more about this fascinating topic from world-renowned speakers! Submit your abstract before 29 July and register before 09 September to secure your place.

Conference Officer: Hannah Barrs;     Tel.: [N/A];     Email: hannah.barrs@eacr.org

cancer research, oncology, therapeutic targets, cancer drug discovery, drug discovery approaches, new technical approaches to cancer therapeutics, early clinical development, small molecule technology, phenotypic screens, covalent fragment screens, degrader technology, PROTAC, molecular glue, peptide technology, oral cyclic peptide inhibitors, antibody technology, antitumour approaches, antibody drug conjugates, targeting RAS, targeting mutant p53.

The European Association for Cancer Research (EACR)

This conference aims to illuminate the intricate dynamics between ageing and cancer, fostering interdisciplinary dialogue among researchers and clinicians. By understanding the biological dimensions of cancer in ageing populations, we aspire to drive innovations in prevention, diagnosis, and treatment strategies. Ultimately, the conference seeks to catalyse collaborative efforts to confront the unique challenges posed by cancer in the ageing world, with the overarching goal of improving the quality of life and outcomes for elderly cancer patients. This conference is relevant for a diverse range of researchers, clinicians, and industry professionals. We look forward to being joined by: scientists and academics working in oncology, gerontology, genetics, and related disciplines; clinical oncologists, geriatricians, and other healthcare professionals who play a crucial role in diagnosing, treating, and supporting elderly patients with cancer; and representatives from pharmaceutical companies and biotechnology firms which develop innovative therapies and technologies to combat cancer in ageing populations. Join us online on 03 and 04 December to learn more about this fascinating topic from world-renowned speakers! Submit your abstract before 14 October and register before 11 November to secure your place.

Conference Officer: Chris Iliffe;     Tel.: [N/A];     Email: christopher.iliffe@eacr.org

cancer research, oncology, ageing, ageing hallmarks, senescence, immunosenescence, inflammaging, aged tumour microenvironment, cancer prevention, cancer diagnosis, cancer treatment, elderly patients, treatment advances

The European Association for Cancer Research (EACR), in conjunction withAstraZeneca

Conference Officer: Hannah Barrs;     Email: hannah.barrs@eacr.org

cancer research, oncology, circulating tumour DNA, cell-free DNA, liquid biopsy, early cancer detection, clinical trial design, breast cancer, lung cancer, colorectal cancer, bladder cancer, virtual cancer research conference

The European Association for Cancer Research and Boehringer Ingelheim

We return to this topic for its second edition to focus on the basic and clinical aspects of the regulation of the Mitogen Activated Protein Kinase (MAPK) pathway, one of the most commonly mutated signalling pathways in human cancers. The programme will include new insights about the mechanisms of action of the new generation of pan-RAS inhibitors and rational combination therapies.

Email: christopher.iliffe@eacr.org

cancer research, oncology, MAPK pathway, small molecule inhibitors, intrinsic resistance, adaptive resistance, effective cancer therapy agents, pan-RAS inhibitors, gene regulation, target validation, drug development, clinical and translational opportunities, rational combination therapies, cross-resistance to immune modulators

Molekularbiologie,    Pharmakologie und Arzneimittelentwicklung

The European Association for Cancer Research (EACR)

This meeting will delve into the profound consequences cancer can have on the body’s usual functions, and the underlying mechanisms behind these systemic effects. The ultimate goal is to explore how we might manipulate these mechanisms to develop more effective cancer treatments and improve the quality of life of patients with advanced cancer. We’ll be covering a wide range of topics including alterations in peripheral tissue function and the metabolic and inflammatory changes they induce, immune system performance, and cancer cachexia. This conference will be relevant for anyone with an interest in cancer biology, inter-organ communication, the role of cytokines, chemokines, and hormones in cancer, as well as cancer-induced changes in behaviour and metabolism.

Join us online on 25 and 26 February to learn more about this fascinating topic! Submit your abstract before 13 January and register before 03 February to secure your place.

Conference Officer: Hannah Barrs;     Tel.: [N/A];     Email: hannah.barrs@eacr.org

cancer research, oncology, cancer biology, immunology, cancer cachexia, inter-organ communication, liver function, muscle function, adipose tissue function, tissue function, metabolic changes, inflammatory changes, tumour metastasis, novel therapeutic interventions, cytokines, chemokines, hormones, cancer metabolism

Biologie,    Immunologie und Allergie